BACKGROUND: The natural history of bronchial preinvasive lesions and the risk of developing lung cancer in patients with these lesions are not clear. Previous studies have treated severe dysplasia and carcinoma in situ (CIS) on the assumption that most will progress to invasive carcinoma. AIMS: To define the natural history of preinvasive lesions and assess lung cancer risk in patients with these lesions. HYPOTHESIS: Most preinvasive lesions will not progress to invasive carcinoma but patients with these lesions will be at high risk. METHODS: A cohort of patients with preinvasive lesions underwent fluorescence bronchoscopy every 4-12 months and computed tomography of the chest annually. The main end point was the development of invasive carcinoma. RESULTS: 22 patients with 53 lesions were followed up for 12-85 months. 11 cancers were diagnosed in 9 patients. Of the 36 high-grade lesions (severe dysplasia and CIS), 6 progressed to invasive cancers. 5 separate cancers developed at remote sites in patients with high-grade lesions. All cancers were N0M0 and curative treatment was given to 8 of the 9 patients. The cumulative risk of developing lung cancer in a patient with a high-grade lesion was 33% and 54% at 1 and 2 years, respectively. Of the 17 low-grade lesions, none progressed to invasive carcinoma. CONCLUSIONS: Although the risk of malignant progression of individual preinvasive lesions is relatively small, patients with high-grade lesions are at high risk of lung cancer. Surveillance facilitated early detection and treatment with curative intent in most patients.
BACKGROUND: The natural history of bronchial preinvasive lesions and the risk of developing lung cancer in patients with these lesions are not clear. Previous studies have treated severe dysplasia and carcinoma in situ (CIS) on the assumption that most will progress to invasive carcinoma. AIMS: To define the natural history of preinvasive lesions and assess lung cancer risk in patients with these lesions. HYPOTHESIS: Most preinvasive lesions will not progress to invasive carcinoma but patients with these lesions will be at high risk. METHODS: A cohort of patients with preinvasive lesions underwent fluorescence bronchoscopy every 4-12 months and computed tomography of the chest annually. The main end point was the development of invasive carcinoma. RESULTS: 22 patients with 53 lesions were followed up for 12-85 months. 11 cancers were diagnosed in 9 patients. Of the 36 high-grade lesions (severe dysplasia and CIS), 6 progressed to invasive cancers. 5 separate cancers developed at remote sites in patients with high-grade lesions. All cancers were N0M0 and curative treatment was given to 8 of the 9 patients. The cumulative risk of developing lung cancer in a patient with a high-grade lesion was 33% and 54% at 1 and 2 years, respectively. Of the 17 low-grade lesions, none progressed to invasive carcinoma. CONCLUSIONS: Although the risk of malignant progression of individual preinvasive lesions is relatively small, patients with high-grade lesions are at high risk of lung cancer. Surveillance facilitated early detection and treatment with curative intent in most patients.
Authors: D Moro-Sibilot; F Fievet; M Jeanmart; S Lantuejoul; F Arbib; M H Laverribre; E Brambilla; C Brambilla Journal: Eur Respir J Date: 2004-07 Impact factor: 16.671
Authors: S Bota; J B Auliac; C Paris; J Métayer; R Sesboüé; G Nouvet; L Thiberville Journal: Am J Respir Crit Care Med Date: 2001-11-01 Impact factor: 21.405
Authors: Nicola A Foster; Anindo K Banerjee; Jian Xian; Ian Roberts; Francesco Pezzella; Nicholas Coleman; Andrew G Nicholson; Peter Goldstraw; Jeremy P George; Pamela H Rabbitts Journal: Genes Chromosomes Cancer Date: 2005-09 Impact factor: 5.006
Authors: Stephen Lam; Sumithra J Mandrekar; Yaron Gesthalter; Katie L Allen Ziegler; Drew K Seisler; David E Midthun; Jenny T Mao; Marie Christine Aubry; Annette McWilliams; Don D Sin; Tawimas Shaipanich; Gang Liu; Evan Johnson; Andrea Bild; Marc E Lenburg; Diana N Ionescu; John Mayo; Joanne Eunhee Yi; Henry Tazelaar; William S Harmsen; Judith Smith; Avrum E Spira; Jennifer Beane; Paul J Limburg; Eva Szabo Journal: Cancer Prev Res (Phila) Date: 2016-09-22